Functional Mitral Regurgitation

Similar documents
How to assess ischaemic MR?

Guidelines in perspective?

Index. B B-type natriuretic peptide (BNP), 76

What echo measurements are key prior to MitraClip?

I have financial relationships to disclose Honoraria from: Edwards

Primary Mitral Regurgitation

The difficult patient with mitral regurgitation

Regurgitant Lesions. Bicol Hospital, Legazpi City, Philippines July Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Ischemic Mitral Regurgitation

Prof. JL Zamorano Hospital Universitario Ramón y Cajal

Secondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège

AATS Annual Meeting Seattle, WA Irving Kron, M.D. Professor and Chairman Department of Surgery University of Virginia Hospital Charlottesville,

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Professors Carpentier and McGoon Mechanism, resulting from the disease Severity of regurgitation, resulting from the mechanism Echo

MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT)

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

New 3D Quantification of Mitral Regurgitation Severity. Judy Hung, MD Cardiac Ultrasound Laboratory Massachusetts General Hospital Boston, MA

When should we intervene surgically in pediatric patient with MR?

What are the best diagnostic tools to quantify aortic regurgitation?

PISA Evaluation of Mitral Regurgitation. Raymond Graber, MD Cardiac Anesthesia Group University Hospitals Case Medical Center 4/07/2011

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Understanding the guidelines for Interventions in MR. Ali AlMasood

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Chronic Ischemic Mitral Regurgitation

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy

Organic mitral regurgitation

EVALUATION OF CHRONIC MITRAL REGURGITATION: ASSESSING MECHANISMS AND QUANTIFYING SEVERITY 2018 STRUCTURAL HEART DISEASE CONFERENCE June 1, 2018

Cecilia Linde Karolinska University Hospital Stockholm

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

Steven F Bolling Professor of Cardiac Surgery University of Michigan

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Disclosures Rebecca T. Hahn, MD, FASE

Mitral Regurgitation

The echocardiographic assessment of functional mitral regurgitation

Direct Planimetry of Mitral Valve Regurgitation Orifice Area by Real-time 3D Transesophageal Echocardiography

DECLARATION OF CONFLICT OF INTEREST. None

8/31/2016. Mitraclip in Matthew Johnson, MD

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices?

LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

Σεμινάρια Ομάδων Εργασίας 2017 Ανεπάρκεια μιτροειδούς μυξωματώδους αιτιολογίας

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

MITRAL REGURGITATION ECHO PARAMETERS TOOL

Secondary mitral valve regurgitation: hemodynamic and numerical insights towards a patient-tailored approach.

Quantifying Aortic Regurgitation

Assessing Function by Echocardiography in VHD Asymptomatic Severe Organic MR. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

What the Cardiologist needs to know from Medical Images

Νεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology

TREATMENT OF SECONDARY MITRAL REGURGITATION VIA PERCUTANEOUS ANNULOPLASTY

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Echocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016

Congestive Heart Failure or Heart Failure

Imaging to select patients for Transcatheter TV

Secondary Mitral Regurgitation: When Should We Intervene?

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

E/Ea is NOT an essential estimator of LV filling pressures

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

MR echo case. N.Koutsogiannis Department of Cardiology University Hospital Of Patras

LUST trial. Echocardiography USER S MANUAL

Aortic stenosis with concomitant mitral regurgitation

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

Surgical repair techniques for IMR: future percutaneous options?

MitraClip in the ICCU: Which Patient will Benefit?

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

When Does 3D Echo Make A Difference?

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

ASE Guidelines on Aortic Regurgitation What Do I Measure? Case Studies

Echocardiography. Guidelines for Valve and Chamber Quantification. In partnership with

10/7/2013. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast. Thanks to our Course Director: Neil J.

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Marti McCulloch, BS, MBA, RDCS, FASE Houston, Texas

Valvular Intervention

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Rational use of imaging for viability evaluation

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea

Doppler Basic & Hemodynamic Calculations

ΓΙΩΡΓΟΣ ΜΑΚΑΒΟΣ, MD, PhD ΚΑΡΔΙΟΛΟΓΟΣ, ΕΠΙΜΕΛΗΤΗΣ Β Γ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Γ.Ν.Ν.Θ.Α. ΣΩΤΗΡΙΑ

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

True morphology of mitral regurgitant flow assessed by three- dimensional transesophageal echocardiography

3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD

Severe left ventricular dysfunction and valvular heart disease: should we operate?

13/06/2018. Rheumatic Mitral Stenosis: What does the ESC Guideline say? Mitral Stenosis: Echo Assessment. Mitral Stenosis ESC Guidance 2017

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Transcatheter Mitral Valve for fmr: The Era of Too Many Options

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.

University of Groningen. New insights into the surgical treatment of mitral regurgitation Bouma, Wobbe

Transcription:

Club 35 - The best in heart valve disease - Functional Mitral Regurgitation Steven Droogmans, MD, PhD UZ Brussel, Jette, Belgium 08-12-2011 Euroecho & other Imaging Modalities 2011 No conflicts of interest

Functional Mitral Regurgitation Definition Anatomy & mechanisms Echocardiographic assessment Prognostic implications Treatment options Summary: the role of echo

Definition Secondary MR < LV-disease: global dilated cardiomyopathy of any cause regional LV-dysfunction ( ischemic MR ) Distortion of LV geometry and function: imbalance tethering and closing forces Normal mitral valve apparatus Frequent: 50% post AMI or dilated CMP

Prognostic implications Grigioni F et al. Circulation 2001;103:1759-1764

Anatomy & mechanisms Reduced closing forces Increased tethering forces decreased LV-function change annular contraction synchronicity PM LV dyssynchrony Apical displacement PM Annular dilatation Ischemic MR: regional WMA - eccentric jet Global LV dilatation: central jet

Anatomy & mechanisms Functional Ischemic MR

Functional Ischemic MR WM abnormalities and PM displacement: asymmetric MR

Global LV dilatation Altered geometry sphericity annular dilatation structural normal leaflets

Echocardiographic assessment Mitral valve morphology success of repair Severity of MR - prognostic implications LV morphology and function: LV volume, EF Dyssynchrony WMA scar? Viability (dobu) Dynamic changes of MR Prognosis and management of functional MR

Echocardiographic assessment

Mitral Valve Watanabee JACC 2006 Grewal Circulation 2010 Mor-Avi Circulation 2009 Maruo, Abstract ESC 2011

Mitral valve and LV parameters

LV geometry and function

Mitral valve closing force Piérard L A, Carabello B A Eur Heart J 2010;31:2996-3005

Unfavourable parameters of MV repair

Severity of MR Semi-quantitative Colour flow mapping Vena contracta width Limitations Technical factors (Gain settings, PRF) Eccentric jets Loading conditions Left atrial size Limitations Lateral resolution Phasic changes Multiple jets Non-circular orifice

Severity of MR Semi-quantitative Colour flow mapping Vena contracta width Usefull for diagnosis indirect estimation of severity Two orthogonal planes VC < 0.3 cm: mild MR VC 0.7 cm: severe MR

Severity of MR: PISA Severe functional MR: EROA 20 mm 2 or a R Vol 30 ml

Severity of MR: pitfalls Non-circular orifices Phasic change of MR during cardiac cycle

Severity of MR: additional parameters Pulsed Doppler CW Doppler MI/AO TVI Pulm. vein

Integrating indices of severity Severe functional MR: EROA 20 mm 2 or a R Vol 30 ml

Dynamic aspect of MR Severity of functional MR at rest does not predict does not reflect severity during exercise Unmask significant MR when rest MR is mildmoderate: 1. Exertional dyspnoea out of proportion MR and LV-function at rest 2. Pulmonary oedema without a cause 3. CABG planned for patients with moderate MR Prognostic relevance

Dynamic aspect of MR Picano, E. et al. J Am Coll Cardiol 2009;54:2251-2260

Exercise-induced dynamic MR ischemic MR Lancellotti et al. Eur Heart J 2005

LV viability: biphasic response

Treatment of functional MR Medical therapy Revascularisation ± Mitral valve surgery Cardiac resynchronisation therapy (CRT) Percutaneous treatment

Medical therapy Medical therapy for heart failure if indicated ACE-inhibitor beta-blocker aldactone Reduction of morbidity/mortality Diuretics symptom reduction

Surgical treatment Mitral valve annuloplasty preferably: probably better outcome preservation mitral (sub) valvular apparatus - maintaining LV geometry preservation LV systolic function reduction LV volume But, high frequency of MVP-failure reported in some series. 28% moderate MR at 6 months and stable thereafter

Surgical treatment Limited study data and controversy about long-term prognosis

Surgical treatment Limited study data and controversy about long-term prognosis????

CABG ± MVP in moderate MR CABG + MVP Better outcome on LV geometry function NYHA No survival benefit after 32 month follow-up (underpowered) Fattouch, JTSC 2009

CABG ± MVP in moderate MR CABG CABG + MVP 35% of patients evolved towards moderate to severe MR Better outcome on LV geometry function NYHA MR improved in all patients No survival benefit after 32 month follow-up (underpowered) Fattouch, JTSC 2009

Predictors of improvement of unrepaired moderate ischemic MR after CABG MR Improvement ( ) and failure ( ) group: 5 dysfunctional viable segments PPM dyssynchrony < 60 ms Penicka M et al. Circulation 2009;120:1474-1481

Preoperative left ventricular dimensions predict reverse remodelling following restrictive mitral annuloplasty in ischemic mitral regurgitation Braun, EJTS 2007

Acute reduction of MR by CRT Kanzaki, JACC 2004

Chronic reduction of MR in DCMP by CRT Matsumoto, AJC 2011

Chronic reduction of MR in DCMP by CRT Chronic Acute effect Matsumoto, AJC 2011

CRT as alternative for moderate to severe MR in inoperable HF? van Bommel R J et al. Circulation 2011;124:912-919

CRT as alternative for moderate to severe MR in inoperable HF? van Bommel R J et al. Circulation 2011;124:912-919

MitraClip

MitraClip

Conclusion: Central role of echocardiography Severity of MR and anatomy mitral valve Risk stratification: EROA > 20 mm 2 in rest Dynamic component EROA > 13 mm 2 increase LV remodelling: LVEDD > 65 mm Success of surgical repair Management: Mitral valve annuloplasty CRT Mitraclip